Literature DB >> 1899347

A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.

J Diéval1, G Nguyen, S Gross, J Delobel, E K Kruithof.   

Abstract

A 36-year-old patient was investigated for a lifelong history of epistaxis and delayed bleeding after minor surgeries. Deficiencies or abnormalities of the coagulation system, of platelet function, or of factor XIII and alpha-2-antiplasmin were excluded. Consistently, however, over a period of 7 years, a high basal euglobulin fibrinolytic activity was observed that was characterized by a high tissue-type plasminogen activator (t-PA) activity, normal t-PA antigen, and undetectable plasminogen activator inhibitor type-1 (PAI-1) antigen and activity. The high specific activity of t-PA (640,000 IU/mg) and the minimal amounts of t-PA/PAI-1 complexes detected by fibrin zymography suggest that in this patient all t-PA was active. This is in striking contrast to normal plasma, where the majority of t-PA is complexed to PAI-1. Thus, in this patient, a severe deficiency of PAI-1 is associated with a delayed type bleeding tendency. Our observation underscores the importance of plasma PAI-1 for the stabilization of the hemostatic plug.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899347

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha.

Authors:  C Fearns; D J Loskutoff
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

Review 2.  Angiotensin converting enzyme inhibitors--do they have an anti-ischemic action?

Authors:  J D Rutherford
Journal:  Trans Am Clin Climatol Assoc       Date:  1996

Review 3.  Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease.

Authors:  Victoria A Ploplis
Journal:  Curr Drug Targets       Date:  2011-11       Impact factor: 3.465

Review 4.  Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.

Authors:  D de Bono
Journal:  Br Heart J       Date:  1994-06

Review 5.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 6.  PAI-1 in tissue fibrosis.

Authors:  Asish K Ghosh; Douglas E Vaughan
Journal:  J Cell Physiol       Date:  2012-02       Impact factor: 6.384

7.  Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.

Authors:  P Carmeliet; J M Stassen; L Schoonjans; B Ream; J J van den Oord; M De Mol; R C Mulligan; D Collen
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

8.  Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide.

Authors:  F Samad; K Yamamoto; D J Loskutoff
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

9.  Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.

Authors:  M S Sawdey; D J Loskutoff
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

10.  Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease.

Authors:  Tessa M Simone; Paul J Higgins
Journal:  Mol Med Ther       Date:  2012-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.